DHR

LONGINSIDER SELL

DANAHER CORP DEL

Funds

Score

6.00

vs SPY

-20.0%

Stock return (since Q-end)

-3.7%

SPY return (since Q-end)

+16.3%

Current price

$182.67

News Summary

Negative

Danaher beat Q1 2026 EPS estimates and raised full-year guidance, with bioprocessing orders surging 30% YoY signaling a potential multi-year cycle. However, the company missed revenue by ~$106M, faces margin pressure in diagnostics, and is executing a massive $9.9B Masimo acquisition simultaneously with a CFO transition, while shares have declined 25% YTD despite positive earnings guidance.

Red flags

•Revenue missed consensus by $106M (~1.8%) despite EPS beat, indicating core business softness
•Diagnostics segment core sales declined 4% with margin compression to 27.9% due to China pricing pressure and weakening respiratory testing
•CFO transition (McGrew to Gugino) occurring concurrently with $9.9B Masimo acquisition integration presents material execution risk
•Stock down 25.35% YTD and 6.15% over 1-year despite raised guidance, signaling significant investor loss of confidence
•Multiple analyst price target cuts post-earnings (Morgan Stanley $270→$255, Wolfe $260→$230, JPMorgan $275→$245, Goldman $265→$230)
•New €3.0B debt issuance and expanded borrowing facility to fund M&A increases leverage during period of core revenue deceleration

Funds Buying (4)

Fund	Manager	Shares Held	∆ Shares	Position Value	QoQ	Status
D1 Capital	Dan Sundheim	2.3M	+2.3M	$436.9B	—	NEW
Maverick Capital	Lee Ainslie	820K	+820K	$155.4B	—	NEW
Third Point	Dan Loeb	525K	+525K	$99.5B	—	NEW
Glenview Capital	Larry Robbins	156K	+156K	$29.6B	—	NEW

Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter.

Insider Activity

Name	Title	Type	Shares	Price	Value	Filed
SPOON ALAN G	—	SELL	1K	$174.67	$0.24M	2026-05-01